Goldman Sachs downgraded Kyowa Kirin (KYKOF) to Sell from Neutral with a 2,250 yen price target The firm believes the company’s favorable medium-term earnings outlook is now largely priced in following recent strong performance in the share price, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYKOF:
- Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
- Kyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
- Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
- Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
- Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia